Vivo Bio Tech DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.83×	0.62×
	0.77×	0.34×
	25.2%	26.3%
	0.34×	0.33×
	1.81×	2.48×
	10.0%	4.6%
	11.4%	4.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health

₹ CroreMcap ₹21.4 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.62	0.83
Interest Burden (Pretax/EBIT) ×	0.34	0.77
EBIT Margin %	26.28	25.24
Asset Turnover ×	0.33	0.34
Financial Leverage (Assets/Equity) ×	2.48	1.81
ROE (5-step product, year-end total equity) %	4.60	9.97
ROE (owners' profit / average owners' equity) %	4.64	11.42

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.